Cutaneous and visceral leishmaniasis during anti-TNFα therapy.
The long-term use of novel antipsoriatic systemic biotechnological drugs may increase susceptibility to opportunistic infections. Several cases of visceral leishmaniasis have been reported in immunosuppressed individuals, including those who have been treated with tumour necrosis factor alpha (TNFα) blocking agents. Simultaneous occurrence of cutaneous and visceral involvement has been more rarely recorded in the medical literature. Herein, we describe a case of mucosal leishmaniasis occurring in a farmer living in an endemic region, who was treated with golimumab because of psoriatic arthritis. This highlights the importance of recognizing cutaneous lesions as a first indicator of possible underlying kala-azar disease.
Department of Clinical Experimental Medicine, Unit of Dermatology, University of Messina, C/O A.O.U. "G. Martino", via Consolare Valeria 1, 98125, Messina, Italy.
Claudio
C
Guarneri
Unit of Dermatology at A.O.R.N.A.S. "G. Garibaldi" and Department of General Pathology, University of Catania, Piazza Santa Maria del Gesù, 95125, Catania, Italy.
Valentina
V
Bevelacqua
Department of Pathology, Department of Dermatology, University of Virginia Health System, 1215 Lee Street, Box 800214, 22908, Charlottesville, VA, USA.
James W
JW
Patterson
Department of Dermatology, Venereology and Dermatologic Surgery, Medical Institute of Ministry of Interior (MVR), General Skobelev blvd. 79, 1606, Sofia, Bulgaria. georgi_tchernev@yahoo.de.
Georgi
G
Tchernev
D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use*; D015535:Arthritis, Psoriatic / Q000188:drug therapy*; D001706:Biopsy; D001853:Bone Marrow / Q000473:pathology; D003937:Diagnosis, Differential; D006801:Humans; D007893:Leishmania donovani; D007897:Leishmaniasis, Mucocutaneous / Q000139:chemically induced* / Q000175:diagnosis* / Q000473:pathology; D007898:Leishmaniasis, Visceral / Q000139:chemically induced* / Q000175:diagnosis* / Q000473:pathology; D008047:Lip Diseases / Q000139:chemically induced* / Q000175:diagnosis* / Q000473:pathology; D008297:Male; D009894:Opportunistic Infections / Q000139:chemically induced* / Q000175:diagnosis* / Q000473:pathology; D014409:Tumor Necrosis Factor-alpha / Q000009:adverse effects* / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; C529000:golimumab
Arthritis; Golimumab; Leishmania; Leishmania infantum; Psoriasis